RESUMO
BACKGROUND: Nasal congestion is a chronic symptom of seasonal allergic rhinitis (SAR) that is often difficult to treat with antihistamines. Desloratadine, a new, potent, H1-receptor antagonist has been shown to decrease nasal congestion in clinical trials and to maintain nasal airflow in response to grass pollen exposure. We compared the effects of desloratadine 5 mg and placebo on nasal airflow, nasal secretion weights and SAR symptoms, including nasal congestion, in patients exposed to grass pollen in an environmental exposure unit. METHODS: Forty-six grass pollen allergic SAR patients received desloratadine or placebo for 7 days, followed by a 10-day washout, and then crossed over to the other treatment for 7 days. A 6-h allergen exposure was performed at the end of each treatment period. RESULTS: Desloratadine was significantly superior to placebo in maintaining nasal airflow (P Assuntos
Antagonistas não Sedativos dos Receptores H1 da Histamina/administração & dosagem
, Loratadina/administração & dosagem
, Cavidade Nasal/fisiopatologia
, Ventilação Pulmonar/efeitos dos fármacos
, Rinite Alérgica Sazonal/tratamento farmacológico
, Rinite Alérgica Sazonal/fisiopatologia
, Adulto
, Estudos Cross-Over
, Método Duplo-Cego
, Esquema de Medicação
, Exposição Ambiental
, Feminino
, Antagonistas não Sedativos dos Receptores H1 da Histamina/efeitos adversos
, Humanos
, Loratadina/efeitos adversos
, Loratadina/análogos & derivados
, Masculino
, Cavidade Nasal/efeitos dos fármacos
, Mucosa Nasal/metabolismo
, Placebos
, Poaceae/imunologia
, Pólen/imunologia